Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
T-cell-redirected lysis triggered by bispecific antibodies recruiting T cells to cancer cells is a clinically validated mechanism of action against hematologic malignancies and CD38 is a tumor-associated antigen with near-universal expression in multiple myeloma.
|
30918018 |
2019 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.
|
31186046 |
2019 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the role of CD38 in non-hematological malignancies has not been explored.
|
29228209 |
2018 |
Hematologic Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chimeric antigen receptor T cells (CAR-Ts) are a promising strategy for the treatment of many cancers, including multiple myeloma (MM), a hematological malignancy characterized by the high expression of CD38.
|
30185037 |
2018 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients deemed fit to receive T10-based conditioning for allogeneic stem-cell transplantation to treat high-risk hematologic malignancies had better overall and progression-free survival than those who received T5 with no additional toxicities.
|
29625929 |
2018 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, CD38 antibodies are currently also under investigation in other hematologic malignancies, including acute lymphoblastic leukemia, natural killer/T-cell lymphoma, and acute myeloid leukemia, as well as in solid tumors.
|
29118010 |
2018 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ten-eleven translocation (TET) family of enzymes were originally cloned from the translocation breakpoint of t(10;11) in infant acute myeloid leukemia (AML) with subsequent genomic analyses revealing somatic mutations and suppressed expression of TET family members across a range of malignancies, particularly enriched in hematological neoplasms.
|
28242787 |
2017 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aim was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for hematological malignancies.
|
29084989 |
2017 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, CD38 antibodies may have a role in the treatment of diseases beyond hematological malignancies, including solid tumors and antibody-mediated autoimmune diseases.
|
26864107 |
2016 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ecto-enzyme CD38 is gaining momentum as a novel therapeutic target for patients with hematological malignancies, with several anti-CD38 monoclonal antibodies in clinical trials with promising results.
|
24990614 |
2015 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
|
24987056 |
2014 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expanded fold values of CD45(+) white blood cells and CD34(+), CD133(+), CD34(+)CD38(-), CD133(+)CD38(-), CD34(+)CD133(+), colony-forming and long-term culture-initiating cells at the end of 7-day culture from CD133(+) MPB of hematologic malignancies were 9.4-fold, 5.9-fold, 4.0-fold, 35.8-fold, 21.9-fold, 3.8-fold, 11.8-fold and 6.7-fold, and values from healthy donor CD133(+) MPB were 20.7-fold, 14.5-fold, 8.5-fold, 83.8-fold, 37.3-fold, 6.2-fold, 19.1-fold and 14.6-fold.
|
23768928 |
2013 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Hematologic malignancies with the t(10;11) (p13;q21) have the same molecular event and a variety of morphologic or immunologic phenotypes.
|
9365832 |
1997 |